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Abstract: Due to complex interdependent relationships affecting their microstructure, topical semisolid
drug formulations face unique obstacles to the development of generics compared to other drug
products. Traditionally, establishing bioequivalence is based on comparative clinical trials, which
are expensive and often associated with high degrees of variability and low sensitivity in detecting
formulation differences. To address this issue, leading regulatory agencies have aimed to advance
guidelines relevant to topical generics, ultimately accepting different non-clinical, in vitro/in vivo
surrogate methods for topical bioequivalence assessment. Unfortunately, according to both industry
and academia stakeholders, these efforts are far from flawless, and often upsurge the potential for
result variability and a number of other failure modes. This paper offers a comprehensive review of
the literature focused on amending regulatory positions concerning the demonstration of (i) extended
pharmaceutical equivalence and (ii) equivalence with respect to the efficacy of topical semisolids.
The proposed corrective measures are disclosed and critically discussed, as they span from mere
demands to widen the acceptance range (e.g., from ±10% to ±20%/±25% for rheology and in vitro
release parameters highly prone to batch-to-batch variability) or reassess the optimal number of
samples required to reach the desired statistical power, but also rely on specific data modeling or
novel statistical approaches.
Keywords: generic semisolid drug product; extended pharmaceutical equivalence; equivalence with
respect to efficacy; qualitative and quantitative composition; microstructure; in vitro release testing;
in vitro permeation testing; tape stripping
1. Introduction
Topical semisolid drug products are among the oldest medicinal dosage forms known
to human civilization, widely used in treating a variety of skin diseases. Despite their
importance and long history of use, the innovations in semisolid products generally lag
behind other pharmaceutical product classes. Since topical products commonly produce
lower revenues, the development of both novel and generic products is hindered by the
projected return on investment-related risks [1]. Namely, the pharmaceutical industry
is to invest significant resources to demonstrate the quality, efficacy, and safety of any
product before the authorities grant its market authorization [2]. Semisolid formulations,
such as ointments, creams, and gels, due to an extremely complex microstructure (i.e., the
microscale arrangement of matter and state of aggregation), are accompanied by more
complicated, interdependent relationships among the structure, properties, manufacturing
process, and performance as compared to solid and injectable dosage forms, that increase
the potential for variability and number of failure modes [3,4]. Furthermore, topical
drug products face unique obstacles to the development of generics compared to other
drug products for which the assessment of bioequivalence is amenable to traditional
pharmacokinetic methods [1,5].
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As the target site of the most topical semisolid formulations is either the skin or
the underlying tissue, due to the none or very low measurable amounts of drug in the
systemic circulation, traditionally, establishing bioequivalence in most cases has been
based on comparative clinical trials, which are time consuming and expensive, but more
importantly, often associated with a high degree of variability and low sensitivity in
detecting formulation differences [5–9]. In general, clinical trials require the demonstration
of bioequivalence of the prospective generic to the reference/comparator drug product,
using one or more clinical endpoints and guaranteeing efficacy by establishing superiority
of the tested formulation over a placebo [10]. A clinical response to topical drugs is quite
variable due to the numerous patho-physiological factors as well as difficulties involved in
the standardization of the applied dose [9]. Likewise, in such cases there is no true placebo
since the vehicle components also exert some effects, making the primary endpoints of
clinical trials more difficult to meet [2]. As a result, despite the enrollment of a large number
of patients in clinical trials (n > 500), frequently, the formulation differences cannot be
efficiently detected [10]. This represents a substantial challenge to generic manufacturers
and an additional cost for the patients [9]. Indeed, in U.S., in the 2011–2015 period, a
significant price increase (almost 276%) was observed for topical generic products, while,
simultaneously, oral generic drugs demonstrated a price decrease (21%) [1]. In order
to improve the patient access to more affordable topical semisolid drug products on
the market, demonstration of bioequivalence requires the usage of alternate approaches
which are faster, less expensive, more reproducible, and sensitive to differences in topical
products [1,9].
In this context, firstly, to optimize the regulatory requirements for the therapeutic
equivalence of topical semisolid drug products, pharmaceutical scientists and dermatol-
ogists from academia, industry and regulatory agencies, have proposed the Strawman
decision tree and the topical drug classification system [9,10]. Both these approaches
highlighted the importance of accounting product specificities, including the proper-
ties of pharmaceutical form, drug, site of action and indication. The information on
qualitative/quantitative composition and microstructure of the semisolid products being
compared represents the basis for rational selection of relevant in vitro/in vivo product
performance measures for the determination of bioequivalence [5,9–11]. As a result, within
the last few years, both European and American regulatory authorities have been ad-
vancing regulation relevant to topical generic products, accepting different non-clinical,
in vitro/in vivo surrogate methods for topical bioequivalence assessment [12]. From 2012,
U.S. Food and Drug Administration (FDA) has continuously published non-binding,
product-specific guidelines for generic product development, to identify the appropriate
methodology for developing drugs and generating evidence needed to support abbreviated
new drug application (ANDA) approval [13]. Over the past five years, a number of relevant
guidelines were made public, including an in vitro option to establish bioequivalence of
topical semisolid drug products [10,11] (Table 1). As outlined in Table 1, specific in vitro
tests that should be performed to support a claim of therapeutic equivalence, in lieu of
clinical endpoint studies, highly depend on intrinsic complexity of a specific product.
Table 1. FDA non-binding product-specific draft guidelines for topical generic semisolid drug products that contain in vitro















In Vivo Study Year
Acyclovir Ointment + + + 2019
Acyclovir Cream + + + + 2016
Bexarotene Gel + + + + 2019
Ciprofloxacin
hydrochloride Ointment + + + 2018
















In Vivo Study Year
Clindamycin




Gel + + + 2020
Crisaborole Ointment + + + + PK 2019
Crotamiton Cream + 2016
Dapsone Gel + + + + PK 2019
Docosanol Cream + + + 2017
Doxepin
hydrochloride Cream + + + + PK 2019
Gentamicin sulfate CreamOintment + 2017
Hydrocortisone Cream + 2017
Ivermectin Cream + + + + PK 2019
Lidocaine Ointment + + 2016
Luliconazole Cream + + + + 2018
Metronidazole Gel + + + 2019







hydrochloride Cream + + + + 2019
Ozenoxacin Cream + + + + 2019
Penciclovir Cream + + + + 2018
Pimecrolimus Cream + + + + 2019
Silver sulfadiazine Cream + + + 2017
Tacrolimus Ointment + + + + 2018
Tretinoin Gel + + + 2020
Tretinoin Cream + + + CES 2020
+ indicates methods recommended by the guidelines; PK—in vivo pharmacokinetic study in humans; CES—clinical endpoint studies.
On the other hand, in October 2018, European Medicines Agency (EMA) published for
public consultation a universal guideline for topical generic product submission entitled
Draft Guideline on Quality and Equivalence of Topical Products. Due to the high diversity of
topical products, the complex range of skin conditions that should be treated and the variety
of patient needs, this guideline does not provide a single procedure, but states that general
recommendations should be adopted on a case-by-case basis [14]. Despite the obvious
differences in the manner of proposing the recommendations for generic drug development,
EMA requirements are generally similar to those of the FDA. Precisely, according to
EMA draft guideline, in case of simple semisolid formulations (e.g., gels, ointments),
therapeutic equivalence can be extrapolated from the comparative quality data with the
relevant comparator medicinal product (extended pharmaceutical equivalence concept).
For this purpose, comparative analysis of pharmaceutical form, qualitative and quantitative
composition, microstructure/physical properties, product performance and administration
should be performed. In case of complex formulations (e.g., multiphase systems) or
those comprising excipients that might affect drug bioavailability and performance, an
additional biorelevant test, such as permeation kinetics (in vitro skin permeation, tape
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stripping or pharmacokinetic bioequivalence) or pharmacodynamic (vasoconstriction assay
for corticosteroids or tests relevant for antiseptics and anti-infectives) studies, should be











bioequivalence methodologies. Despite  the  significant  advances made  in  the develop‐
ment of generic semisolid products, several limitations have been identified, restricting 
its successful  translation  into practice  [15]. Therefore,  this  review  intends  to provide a 
comprehensive  insight  into  the  implications of  the proposed regulatory  framework  for 
equivalence demonstration  for  generic  semisolid products,  analyzing  the more  recent 
data obtained during extended pharmaceutical equivalence characterization, as well as 
efficacy equivalence studies. The strengths and  limitations of each regulatory accepted 







Drug delivery at  the  target skin site  from  topical semisolid products  is a complex 
phenomenon, which depends on  the drug physiochemical properties,  the disease state 
and  in particular,  formulation effects  [9]. The  formulation composition  (excipients’ na‐
ture and concentration) is crucial for the therapeutic efficacy, since it directly affects drug 
solubility and thermodynamic activity, drug release from the dosage form, skin barrier 





whose  function  is not related  to product performance and administration  (i.e., antioxi‐
dants, preservatives, coloring agents) could be qualitatively and quantitatively different 
(not more than ±10% is acceptable) [14]. Since the excipients in the comparator product 
are  listed  in  the patient  information  leaflet,  establishing  the Q1  sameness  seems  to be 
relatively simple. On the other hand, in order to achieve Q2 sameness, reverse engineer‐
Figure 1. Schematic illustration of the proposed regulatory fra e ork for bioequivalence assess ent of topical semisolid
drug products according to recently issued EMA draft guideline.
o ever, it s o l be ote t at t e ro ose raft guideline is the subject of
intensive aca e ia a i stry- i e isc ssio s, seeking reliable and robust surrogate
bioeq i ale ce et o ologies. Despite the significant advances made in the develop-
e t of generic se isoli ro cts, several li itations ave been identified, restricting
its successf l tra slatio i to ractice [15]. Therefore, this review intends to provide a
co re e si e i si t i to t e i licatio s of t e ro osed regulatory framework for
equivalence demonstration for generic semisolid products, analyzing the more recent data
obtained during extended pharmaceutical equivalence characterization, as well as efficacy
equivalence studies. The strengths and limitations of each regulatory accepted method are
presented in brief, including their suitability for abridged bioequivalence demonstration
of generic semisolid drug products. Particular attention was given to solutions proposed
for constraints hamperi g the applicability of currently available regulatory guidelines
in practice.
2. emonstration of Extende Pharmaceutical Equivalence of Topical Semisolid Drug Prod cts
2.1. Evaluation of Qualitative (Q1) and Quantitative (Q2) Sameness
Drug delivery at the target skin site from topical semisolid products is a complex
phenomenon, which depends on the drug physiochemical properties, the disease state
and in particular, formulation effects [9]. The formulation composition (excip ent ’ nature
an concentration) is crucial for the therap utic efficacy, since it directly aff ct drug
solubility a d thermodynamic activity, drug r leas from the dosage form, skin ba rier
properties and drug penetration/diffusion into/through skin [16]. Therefore, both
European and American regulatory a thorities require the demonstration of acceptable
Q1 and Q2 sameness, i.e., to document at he test p oduct contains the same excipients
in the same quantitativ compositio as the comparator medicinal product (differe ces
not greater than ±5% ar acce table). According to EMA draft guideline, only excipients
whose function is not related to product performance and administration (i.e., antioxidants,
preservatives, coloring agents) coul be qualitatively quantitatively different (not
more than ±10% i acceptable) [14]. Since the excipients i the comparator product
are listed in the patient information leaflet, stablishing the Q1 sameness seems to be
relatively s mpl . On the othe h nd, in order to ch eve Q2 sameness, reverse engineering
Pharmaceutics 2021, 13, 710 5 of 19
of the comparator product needs to be performed, applying appropriate and validated
analytical methods [2,15]. However, due to patent pending or undesirable quality outcome,
manufacturers of generic semisolid products are sometimes compelled to modify the
formulation composition of the comparator product, and consequently, accomplishing
the Q1/Q2 sameness could be a quite challenging task [15,17]. Additionally, as stated
in EMA draft guideline, not only formulation composition, but also, the grade of the
excipients should be the same, due to its significant impact on the product quality and
performance [15,18,19]. For example, analyzing the effect of 6 different petrolatum sources
on drug product performance containing petrolatum as the only vehicle, it was observed
that diverse grades of petrolatum produced significantly different release rates of a topical
steroid, due to variations in the distribution ratios of the hydrocarbons chain lengths [19,20].
However, the grade of excipients used in a comparator product is only available to the
regulatory agencies. It is quite demanding to experimentally analyze the grade of any
excipient within semisolid formulations, and therefore, assuring the sameness of excipient
grades could be difficult to achieve for most generic manufacturers [15].
Although demonstration of Q1/Q2 sameness is considered critical in reducing the fail-
ure modes related to the product performance, the variations of key functional excipients,
even within the acceptable range (±5%, w/w), can significantly affect the drug bioavail-
ability. In this regard, the results of a recent study performed by Kumar Sharma et al. [21]
deserve to be mentioned here, since it investigated the effects of incremental changes in
the surfactant concentration (±5%, w/w) on the quality and performance attributes of
metronidazole-loaded cream products that meet the definition of Q1/Q2 sameness. Al-
though the monitored quality attributes (globule size, rheology, pH, water activity, rate
of drying) practically overlapped, in vitro permeation profiles were remarkably different
between the tested formulations. Acceptable 5% w/w change in surfactant concentration
obviously led to significant change in the degree of drug saturation during product evapo-
rative metamorphosis, ultimately influencing its performance [21]. This study confirmed
that the change in drug thermodynamic activity during metamorphosis, due to slight
variations in formulation composition, could significantly alter the drug bioavailability. Al-
though EMA draft guideline asserts that for volatile solvent based topical products, product
transformation on administration should be also compared, no methodologies have been
proposed for this purpose [14,15]. Therefore, again, the requirement regarding product
metamorphosis sameness proves to be difficult to attain. In other words, although different
methods have been proposed in the literature (e.g., ATR-FTIR spectroscopy, localized
nanothermal analysis and photothermal microspectroscopy combined with multivariate
data analysis) [15], there are still limited data on their applicability for the characterization
of a wide range of topical semisolid products. Therefore, it is essential that EMA provides
more detailed recommendations for studying the product metamorphosis.
2.2. Comparative Characterization of Critical Quality Attributes (CQAs)
Although the criteria for Q1/Q2 sameness are met, due to complex formulation com-
position and manufacturing process parameters, a generic semisolid product may exhibit
differences in the microstructure and arrangement of matter compared to the reference
product, that may impact its quality and performance attributes [6,17,22]. Various factors
determine specific product microstructure, such as size and shape of dispersed particles,
polymorphism, agglomeration, droplet size of the internal phase, excipients’ source/grade,
processing conditions and storage [17,22,23]. Therefore, according to the EMA draft guide-
line, for the demonstration of extended pharmaceutical equivalence, comparative char-
acterization of microstructure/physical properties should be performed, analyzing the
CQAs that can influence drug bioavailability, usability or can indicate inconsistency in
the manufacturing process and product stability issues. For semisolid formulations, pH
value, density, and rheological behavior are identified as the main risk factors that should
be closely monitored to gain an assurance of microstructural similarity. For suspension
and immiscible phase formulations, additional characterization in terms of drug particle
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size distribution and polymorphic form, that is, globule size distribution and appearance is
required [14]. The similar requirements are set out in the FDA product-specific guidelines
containing an in vitro option of bioequivalence assessment. Physicochemical characteri-
zation should include comparative analysis of appearance, rheological properties, drug
particle size and size distribution, globule size, pH, water activity, and other potentially
relevant physical and structure similarity characteristics [11,13]. However, it should be
noted that the reliable characterization of microstructure has sparked numerous discussions
among different stakeholders (academia, industry and several regulatory agencies) during
the last few years. Among other, they imposed the following two questions: (i) which qual-
ity attributes are truly critical to the therapeutic performance of topical semisolid dosage
forms, as well as (ii) what are the appropriate methodologies for measuring each of these
quality attributes without disturbing the original product microstructure [3,4]. Currently,
both European and American regulatory authorities do not provide recommendations for
the methods that should be utilized for measuring the mentioned CQAs.
Generally, the rheology of semisolid products is highly sensitive to alternations in
the product microstructure, and therefore, detailed rheological characterization takes the
central role in detection of the potential microstructure differences [22,24]. Furthermore,
rheological characterization serves as a useful quality and stability indicator, which could
provide additional information concerning batch variability, product sensorial properties
(e.g., consistency, spreadability, and feel) and consequently patient compliance [22,25].
Hence, EMA defines specific rheological parameters that should be documented when
characterizing the rheological profile of a given formulation. Precisely, (i) a complete flow
curve of shear stress (or viscosity) versus shear rate, (ii) yield stress, and (iii) the linear
viscoelastic response (storage and loss modulus vs. frequency) should be determined.
Additionally, the product’s behavior should be classified according to shear and time
effects and described using appropriate metrices (viscosities at specified shear rates across
the rheograms (e.g., η100); plastic flow yield stress values; thixotropic relative area (SR);
viscoelastic storage and loss moduli (G’ and G”); apparent viscosity; loss tangent (tan
δ)) [14]. These parameters should be determined in at least three batches of the test and
reference products with at least 12 replicates per batch. In order to declare microstructure
equivalence, the 90% confidence interval (CI) for the difference of means of the test and
reference products should be included within the acceptance limits of ±10% of the ref-
erence product mean, assuming normal distribution of data [14]. This requirement has
been intensively disputed in the literature during the last two years as overly restrictive,
because it does not take into account the intrinsic variability of topical semisolids [15]. In
an attempt to clarify this issue, Pleguezuelos-Villa et al. [23] compared rheological data
of Q1/Q2 equivalent test and reference diclofenac diethylamine-loaded emulgels with
the results obtained from in vivo pharmacokinetic study in 32 healthy volunteers. De-
spite statistically significant difference in rheological parameters (90% CI was outside the
90–111% limits), the investigated products could be considered bioequivalent based on the
in vivo bioavailability assay. This finding suggests that a difference beyond ±10% between
rheological parameters of test and reference products does not necessarily translate into rel-
evant in vivo differences [23]. Similarly, while analyzing the spreadability of three generic
formulations that were shown to be equivalent to the innovator product during clinical
bioequivalence studies, Kryscio et al. [24] observed that the equivalence in spreadability
(inversely proportional to yield stress) is not a prerequisite for product bioequivalence.
In this regard, it should be emphasized that before EMA draft guideline became
available for public consultation, all rheological parameters listed above were not a part
of routine analysis when releasing new bathes, and therefore, limited data regarding the
batch-to-batch variability was available [26]. Hence, Mangas-Sanjuán and coworkers [26]
performed comprehensive rheological characterization of 10 batches of a reference product
(Daivobet® ointment 50 µg/0.5 mg/g, Leo Pharma A/S, Ballerup, Denmark, containing
calcipotriol and betamethasone) to evaluate whether the inter-batch variability of the rhe-
ological parameters allows demonstrating equivalence within a ±10% acceptance range.
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Analyzing the obtained 90% CIs (based on both parametric and non-parametric data analy-
sis), the equivalence for most of the rheological parameters could not be demonstrated. In
other words, due to the relatively high inter-batch variability (>10% for several parame-
ters), an acceptance range of ±10% was inappropriate to declare quality equivalence [26].
Generally, the observed high batch-to-batch variability can be derived from the complexity
of excipient source (excipient intra-supplier variability), small differences in manufacturing
procedure, batch size, storage conditions and aging of the formulations [26,27]. Therefore,
in order to overcome the observed limitations of rheological measurements, the authors
proposed (i) to widen the acceptance range up to ±20% (which corresponds to those for
AUC and Cmax in pharmacokinetic bioequivalence studies) or (ii) to calculate the optimal
number of batches required to reach the desired statistical power based on the batch-
to-batch variability [26]. Similarly, while characterizing three batches of eight reference
blockbuster semisolid drug products in the EU market, Miranda et al. [27] observed that
none of the same product batches could be considered as equivalent according to EMA
criteria, due to the high variability in rheological parameters (at least two rheological
endpoints were statistically different between the batches of the same product). This
clearly confirms the need for establishing new microstructure sameness criteria, taking
into account the intrinsic variability of the product being studied [15,27]. In this context,
Xu and coworkers [28] tried to establish the optimal number of batches and replicates per
batch based on different scenarios of inter-batch and intra-batch variability, to accurately
demonstrate microstructure similarity between two semisolid products. The calculation
of proper sample size is important to disable data manipulation by preventing pharma-
ceutical companies to choose those product batches that behave similarly. Founded on the
simulation-based data analysis, it was concluded that, in cases of low intra- and inter-batch
variability, the minimum number of batches should be three, with minimum six units per
batch. For the products with up to 5% difference, testing six batches with 12 units per batch
or three batches with 24 units per batch could be sufficient to declare equivalence. Finally,
in cases when intra- or inter-batch variability exceeds 10%, the number of batches and/or
the number of units should be further increased [28].
Additionally, it should be emphasized that usual approach for calculation of CI
for the difference of means of the test and reference product, relative to the reference
product mean, does not consider the variability in the reference mean estimate [29]. Hence,
assuming normal data distribution, Ocaña and collaborators [29] proposed new CI for the
test/reference mean ratio, based on the Fieller’s theorem, which takes into account both
the within-batch and the between-batch variance, thus enabling more accurate equivalence
declaration. Due to the relatively large number of rheological parameters that should
be tested as well as high restrictiveness of EMA draft guideline, it was not possible to
demonstrate equivalence even between two packaging formats of the same reference
product (betamethasone ointment 0.5 mg/g). Hence, for multivariate concepts, such as
rheology, Ocaña et al. [29] also suggested to summarize all of the continuous variables to
just one or a few variables by means of principal components analysis technique (PCA)
(for more details, please see Ocaña et al. [29]). Additionally, several studies noticed
that rheological parameters frequently do not follow normal distribution. Therefore, the
calculation of 90% CI based on the ratio of geometric means of test and reference products
seems to be more appropriate [23,26,29].
On the other hand, from a regulatory point of view, the prerequisite for use of rhe-
ology methods as a tool for microstructure characterization of topical semisolids either
for quality control or equivalence demonstration is an appropriate standardization of the
procedure. However, currently, there are no regulatory recommendations for the standard-
ization, i.e., formal validation of this method. Hence, Simões and coworkers [25] tried
to establish a practical approach for validation of the rheological analysis, including the
rheometer qualification and the validation of numerous operational critical parameters
for a rheology profile acquisition. The experimental results showed that the rheology
measurement method can be successfully validated, proving its suitability to determine
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sameness/differences between the formulations. Likewise, obtained findings inter alia
showed that geometry configuration, sample application mode and temperature are critical
method variables that should be carefully optimized before each analysis. According to
the risk assessment analysis, the thixotropic relative area, oscillatory yield point, flow
point, and viscosity related endpoints were defined as highly sensitive and discriminatory
monitoring responses [25]. Hence, it is believed that the early inclusion of rheological
measurements in product manufacture would allow identifying the factors responsible for
microstructure variations, which in turn would assure the satisfying product quality and
reduce the overall batch variability [25].
For immiscible phase formulations, such as creams, globule size may directly affect
the product stability and performance. Poor control of globule size may result in phase
separation, creaming or cracking of the semisolid products [30]. On the other hand, the
alterations in globule size among the prospective generic and reference semisolid drug
products may impact the amount of drug entrapped in the globule, its partitioning between
the oil and water phase, and consequently, drug release and partitioning into the skin [30].
For the given combination of excipients, manufacturing process parameters (e.g., rate of
mixing, temperature, order of excipients addition) may significantly impact the globule
size [30,31]. All these considerations imply the need for careful monitoring of globule size to
ensure the microstructure sameness. However, recent studies imposed several conclusions:
(1) globule size can significantly vary from the batch to batch of the same semisolid
drug product, (2) differences in globule size do not always correlate with differences
in rheology or release profile, and (3) even if EMA criterion for globule size sameness
is not fulfilled, two products can still be bioequivalent (as confirmed in human in vivo
bioequivalence study) [23,27]. Moreover, it is important to highlight how challenging it
may be to analyze the globule size of semisolid products. The characterization of emulsion
droplets is usually performed using optical microscopes coupled with appropriate software
analysis of the globule size distribution (e.g., using free image-analysis software like Image
J, National Institutes of Health, Bethesda, MD, USA), although other techniques have also
been proposed (e.g., morphologically directed Raman spectroscopy, laser diffraction) [32].
Generally, the microscopic analysis requires the measurement of thousands of particles
to obtain statistically valid particle size distribution [32]. Simultaneously, this analysis
is associated with high variability (e.g., coefficient of variation (CV) of almost 38.91%
according to Pleguezuelos-Villa et al. [23]) and requires careful standardization of the
procedure for sample preparation.
Many failure modes of generic semisolid drug products arise from the differences
in the physical and structural properties of the drug compared to the reference product.
Generally, the variations in drug particle size, morphology and polymorphic form may
affect both bulk qualities (such as rheology, density, content uniformity, and other physical
properties) and product performance (such as drug release and efficacy of drug delivery
to the target site) [3]. Indeed, recently, it was observed that the size of drug particles was
one of the main factors determining acyclovir release from cream formulations [33]. As
authors emphasized, particle size of the dispersed acyclovir is the CQA that should be
carefully controlled when developing acyclovir topical creams with desired performance
characteristics [33]. However, it is quite difficult to ensure the same drug particle size and
morphology in the prospective generic product as in the reference product, because they
are highly dependent on the properties of the raw drug. Although milling of the raw drug
can help reduce the particle size and thus obtain comparable sizes to the reference, the
ultimate particle size depends on the solubilization effect of the cosolvents/surfactants
used in the formulations and/or the shearing effects during the homogenization process
of the creams. On the other hand, unlike drug particle size and morphology that can
be relatively easy determined using the microscopic techniques, the characterization of
drug-specific polymorph requires more sophisticated techniques like X-ray diffractometry,
thermal analysis, or others. It can be technically quite difficult to analyze the polymorphic
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form in semisolid products, due to the risk of form conversion, including crystallinity
change, during the sample preparation [32].
A formulation’s pH value may have considerable influence on drug solubility, ioniza-
tion state, polymorphic state, ratio of dissolved to undissolved drug, amount of drug in the
phase in contact with the skin, as well as a formulation’s viscosity and stability, thus deter-
mining the product quality and performance [4]. Likewise, safety and local tolerance of
topical semisolid products may be affected by their pH value, since application of a topical
formulation with pH that markedly deviates from the skin pH may cause irritation, partic-
ularly when accompanied with a skin condition/disease [30]. Considering that the final
product’s pH value is governed by the inherent nature of the drug, excipients interactions
within the formulation, and also by the manufacturing process (e.g., order of components’
addition) [30,31], it is clear that pH, as a CQA, should also be monitored for the demonstra-
tion of extended pharmaceutical equivalence. For example, in acyclovir cream products,
the soluble fraction of acyclovir in the aqueous phase has been identified as the critical
factor for the product performance and its therapeutic outcome. Since acyclovir has two
pKa values (2.27 and 9.25), depending on the pH of the aqueous phase, soluble fraction
of acyclovir may be present in cationic, zwitterionic, and anionic forms, which may have
different skin permeation potential [7]. In this context, recently, Kamal and coworkers [33]
investigated the effects of different formulation variables (propylene glycol, poloxamer and
sodium lauryl sulfate concentrations) and different pHs of the aqueous phase (4, 6.5, 9) on
critical quality and performance attributes of acyclovir cream. Interestingly, the intentional
change in pH of the aqueous phase did not significantly affect acyclovir final concentration
in the aqueous phase, and consequently had negligible effect on acyclovir permeation
and skin retention. It appears that other excipients involved (predominantly propylene
glycol) masked the effect of pH on ionization of acyclovir molecules and their delivery into
and through the skin in vitro [33]. Additionally, it should be noted that, while analyzing
pH values of three batches of eight reference semisolid drug products, Miranda et al. [27]
observed significant inter-batch differences in the pH value, despite the same formulation
and processing conditions. Although, undoubtedly, the same composition and microstruc-
ture attributes (inter alia pH values) related to the comparator product can help ensure the
same therapeutic performance of the prospective generic, both mentioned studies again
impose the conclusion that acceptance limit (90% CI within ±10% of the reference product
mean) proposed by EMA for pH sameness is too restrictive, i.e., more reasonable criteria
should be specified.
Finally, according to EMA draft guideline, comparative analysis of density, as another
important quality attribute, should also be performed during microstructure characteriza-
tion for abridged bioequivalence demonstration. Density of a sample directly affects the
dose withdrawn and applied by patients—the lower dose will be drawn from the formula-
tion with lower density compared to high density one [34]. However, unlike rheological
properties that have been the subject of various studies during the last few years, literature
data whether and how the variations in density of Q1/Q2 equivalent topical semisolid
products affect the product performance are still lacking. Consequently, since acceptance
criteria for a generic product, according to EMA draft guideline, are ultimately dependent
on reference product results [27], detailed investigation of batch-to-batch variability of
density is needed.
2.3. Evaluation of Product Performances—In Vitro Release Test
The release of drug from topical semisolid dosage forms directly affects the onset,
duration and magnitude of therapeutic response, since drug has to be liberated before
being available to the skin. On the other hand, drug release kinetics highly depend on the
combined effect of several physical and chemical parameters of semisolid products, such as
solubility and particle size of the drug, method of drug distribution within the formulation
and rheological properties [10,17,35]. Although not a direct indication of drug bioavail-
ability, an in vitro release test (IVRT), using diffusion cells and synthetic membranes, can
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discriminate the differences in drug release rates arising from the formulation changes
and various physicochemical properties of the semisolid drug products and consequently,
can signal inadequate in vivo performances [35]. Hence, IVRT has been recognized as a
valuable tool at various stages of the generic topical product development (early formula-
tion development phase, scale-up, batch-to-batch consistency, life cycle management, post
authorization changes) [36,37]. As a result, EMA draft guideline define the release rate as
a CQA to be specified in the finished product release and shelf-life specification (unless
otherwise justified). Additionally, a validated IVRT, as a method for product performance
characterization, is required to support extended pharmaceutical equivalence [14]. Here,
it should be noted that 1997 FDA Scale Up and Post Approval Changes for Nonsterile
Semisolid Dosage Forms guidance also recommended IVRT to assure consistent product
performance during the post-approval period after an acceptable level of changes in (i) the
component or formulation composition, (ii) the manufacturing process and equipment,
(iii) scale-up/scale-down of manufacture, or (iv) the site of manufacture of semisolid
products [38]. More recently, in appropriate product-specific guidelines for generic drug
development, the FDA continues to recommend the use of IVRT to support the evaluation
of bioequivalence [13,35,36].
In order to discern potential differences between the test and comparator products,
the following experimental conditions should be carefully selected: (a) membrane type,
(b) composition of receptor medium, (c) test duration, sampling time and experimental
conditions (such as apparatus, temperature, mixing speed), (d) the amount and method of
formulation application and (e) analytical method for quantifying the amount of drug in
the receptor solution [14]. Ideally, a synthetic membrane should act as an inert support that
separates the drug product from the receptor medium without binding the drug, while
simultaneously providing minimal resistance to its release [14,39]. Generally, there are
numerous reports in the literature describing the influence of membrane material on the
drug release (e.g., [39–42]). Considering the obtained findings, it appears that membrane
selection is at least in part drug/formulation dependent, and there are still no useful
recommendations for the selection of the most suitable membrane type for IVRT. Here, it is
interesting to note that Mekjaruskul et al. [39], while analyzing the influence of membrane
type on dexamethasone release, observed that the same membranes with similar average
pore size may yield different release profiles if acquired from different suppliers. This
finding suggests that inter-supplier variability should be also taken into account during
the membrane selection.
Similarly, the receptor medium should be carefully selected in order to maintain
sink conditions during the release experiments [14]. For this purpose, the investigation
of drug solubility in different receptor media should first be performed. Considering
that this step can be quite time consuming, recently, in silico studies using Chemaxon®
software (ChemAxon, Budapest, Hungary) were suggested to rationalize the selection of
solvents suitable for solubility studies, based on respective chemical descriptors (such as
size, geometry, lipophilicity, solubility, and surface topology) arising from drug chemical
structure [37]. According to the EMA draft guideline, the duration of IVRT should be
sufficient to properly characterize the release profile. Ideally, at least 70% of the drug
applied in the donor chamber should be released [14]. However, in vitro release data
obtained during the characterization of eight different topical semisolid drug products
indicate that no more than 50% of the drug tends to be released during the 24-h study [27].
Similar trend was also observed in several other studies which utilized IVRT to assess the
performance of topical semisolid drug products (e.g., [7,43]). Considering that prolonged
assay duration does not mimic in vivo conditions, it is imposed that EMA should reconsider
this requirement [15]. In addition, according to the EMA draft guideline, 12 replicates
with at least six sampling time points within the linear portion of the release profile are
required to thoroughly characterize release process for each product [14]. Subsequently,
hundreds of samples are generated throughout IVRT studies, requiring rapid analysis
of drug content to avoid stability issues. In this sense, aiming to assist manufacturers of
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generic topical semisolid products, Miranda et al. [37] recently established a portfolio of
reversed-phase high-performance liquid chromatography (RP-HPLC) methods specifically
tailored for commercially available topical products for a real-time drug analysis of the
samples generated during the IVRT.
According to recent regulatory requirements, during the marketing authorization pro-
cedure, adequate evidence should be provided to document that IVRT method is properly
validated. The requirements of European and American regulatory authorities are similar,
but significantly more details regarding procedure validation can be found in appropriate
FDA product-specific guideline (Draft Guidance on Acyclovir) [44]. The basic concepts for
validation of the IVRT method are presented in Table 2. Since 2018, an increasing number
of studies deals with validation of IVRT method for different semisolid drug products (e.g.,
acyclovir cream [35], diclofenac emulgel [36], miconazole nitrate cream [45], hydrocortisone
acetate cream [46], metronidazole cream [47]). The first comprehensive report in scientific
literature on the successful qualification/validation of IVRT was published by Tiffner and
coworkers in 2018 [35]. This study is particularly valuable because it provided detailed
procedures for (i) qualification of the IVRT apparatus operational parameters (receptor
chamber capacity, orifice diameter, temperature control, stirring speed, dispensed sampling
volume and environmental conditions), (ii) qualification of the laboratory’s capability to
perform IVRT studies and (iii) validation of HPLC method for drug quantification, which
are stated, but not explicitly described in FDA product-specific guideline [44]. However,
as authors emphasized in the manuscript, the data regarding IVRT method development
(which are required according to both European and American regulatory agencies) are
lacking [35]. Generally, the omission of IVRT method development and validations reports
is considered to be among the main factors impairing the approval of generic semisolid
drug products [36]. Hence, to reduce the time required for method development along
with the overall costs, Miranda et al. [36] proposed an analytical quality by design (aQbD)
approach for development of IVRT method. In brief, after establishment of an analytical
target profile, through the risk assessment analysis, the critical analytical attributes (in vitro
release rate, cumulative amount released at initial/final time point and dose depletion)
and critical method variables (receptor medium, membrane and dose regimen) were iden-
tified. Based on results of a 3 × 2 × 3 factorial design, the most suitable IVRT parameters
were chosen and the comprehensive validations studies of IVRT was further performed,
following the EMA and FDA requirements [36].
Table 2. IVRT method validation and acceptance criteria according to FDA Draft Guidance on Acyclovir [44], EMA Draft
guideline on quality and equivalence of topical products [14] and recent literature reports [35,36,45–47].
Parameter Short Description Acceptance Criteria
Membrane inertness
Evaluation of drug binding to membrane should
be performed by immersing membrane in
solution of drug at concentration relevant to
average drug concentration in the receptor
solution at the end of the test.
The recovery of drug in solution should
be within the range 100% ± 5% [44]
Drug solubility
in the receptor medium
Evaluation of drug solubility in the receptor
mediums should be performed to confirm its
suitability to maintain
sink conditions during the study.
Drug concentration in the receptor
medium should not exceed 30% of its
maximum solubility
in the receptor medium [14]
Linearity, precision
and reproducibility
The R2 value of the in vitro release rate (IVRR)
(slope) should be calculated across the sampling
times throughout the IVRT study duration, for
three IVRT runs with a set of six [44] or 12 [12]
diffusion cells on 3 different days. Precision and
reproducibility should be assessed from
intra-/inter-run data analysis.
Intra−/inter-operator precision and
reproducibility should be also assessed.
Linearity: Minimum R2 > 0.9 across the
study duration is required [14,44].
Precision and reproducibility: CV for the
intra- and inter-run variability should be
<10% [14] or <15% [44]
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Table 2. Cont.
Parameter Short Description Acceptance Criteria
Sensitivity, specificity
and selectivity
Sensitivity should be assessed by comparing the
IVRR from the formulations with high (200%),
low (50%) and nominal drug concentration
(100% of label claim). The specificity should be
assessed by determining whether the changes of
IVRR are proportional to the different drug
concentration in the formulations. The selectivity
should be assessed by determining the capability
of IVRT method to statistically differentiate the
IVRRs from the altered formulations (caused by
changes in drug content, CQAs (e.g., drug
particle size or product rheological profile),
critical manufacturing variables or quantitative
excipient composition).
Sensitivity: mean IVRR (low drug
concentration) < mean IVRR (nominal
drug concentration) < mean IVRR (high
drug concentration); Specificity:
minimum R2 value ≥ 0.90 of the
correlation of formulation concentration
to average IVRR; Selectivity: CI between
altered product formulations should fall
outside the limits 90–111% [14] or
75.00–133.33% [44]
Robustness
Robustness testing should include minor
variations in the method parameters (mixing
rate, temperature, amount of formulation
applied and receptor medium composition)
The mean IVRR of runs under altered
conditions should be within ±15% of the
mean IVRR in the regular
parameter setting [44]
Recovery
The recovery should be calculated by dividing
the average cumulative amount released at the
last point in time with the
applied dose in donor chamber.
The dose depletion ≤30% has no
influence on the steady-state conditions
for drug release [35,36,45–47]
Finally, for the demonstration of extended pharmaceutical equivalence, EMA set
the following requirement: “the 90% confidence interval for the ratio of means of the
test and comparator products for the parameters (R), (A) should be contained within the
acceptance interval of 90–111%” [14]. However, it is important to emphasize that FDA
sameness criterion is not too strict, i.e., 90% CIs of in vitro release rate should be within
75–133.33% [38,44]. As a result, taking into account these requirements, an increasing
number of publications during the last few years has been investigating the sensitivity
and discriminatory capability of IVRT for demonstration of sameness or difference be-
tween semisolid drug products. Recently, while analyzing in vitro performances of Q1/Q2
different test (Calcipotriol/Betamethasone Sandoz®, Lek Pharmaceuticals d.d, Ljubljana,
Slovenia) and reference (Daivobet®, LeoPharma A/S, Ballerup, Denmark) ointments con-
taining fixed combination of calcipotriol and betamethasone, Habjanič et al. [48] observed
significantly higher release rates of both drugs from the test compared to the reference
product. However, the results of clinical study (conducted on 444 male and female adult
patients) showed that differences between these products were not clinically significant and
both products were concluded to be therapeutically equivalent for the topical treatment of
plaque psoriasis vulgaris. Similarly, while comparing the in vitro drug release rates from
three batches, for each of the eight selected reference semisolid products, Miranda et al. [27]
noticed that none of the batches of corresponding product exhibited 90% CI within the
EMA acceptance limits (90–111%), due to high inter-batch variability. Contrary to that,
when wider FDA criteria were applied, the majority of product batches could be considered
as equivalent. These findings clearly underline that EMA should specify more reasonable
criteria for product sameness, considering the intrinsic variability of topical semisolid
dosage forms [27].
3. Demonstration of Equivalence with Respect to Efficacy of Topical Semisolid Drug Products
The complexity of the release mechanisms, the active role of several excipients in the
skin penetration of a given drug, and the changes induced by their interaction with the
biological barrier prospectively restrict the bio-relevance of an IVRT, performed under
infinite dose conditions using synthetic membranes [17]. Therefore, as emphasized in the
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introductory section, according to EMA draft guideline, in the case of complex formu-
lations (such as multiphase systems) or those containing the excipients whose function
is to influence drug bioavailability and product performance (e.g., chemical penetration
enhancers), additional permeation kinetic or pharmacodynamic equivalence data is re-
quired for the demonstration of bioequivalence [14]. Unlike in vivo pharmacodynamic
vasoconstrictor assay that has a long history of use, being recommended by the FDA
(Guidance Topical Dermatological Glucocorticoids: In vivo Bioequivalence (1995)) [49] and other
major regulatory authorities for topical corticosteroid drug products, the acceptance of
dermal pharmacokinetic-based approaches (in vitro permeation testing and tape stripping)
by EMA represents significant progress in regulatory science. Although according to
the Strawman decision tree, confocal Raman spectroscopy and microdialysis have been
proposed as alternative methodologies to study drugs with the target site of action in the
stratum corneum (SC) and epidermis/dermis, respectively [9], EMA emphasized that these
techniques are not sufficiently established to provide pivotal equivalence data, but may be
utilized as a support [14].
3.1. In Vitro Permeation Test
The utility of in vitro permeation test (IVPT) methodology for the documentation
of bioequivalence has been supported by substantial body of evidence showing that
in vitro results correlate well with and are predictive of human in vivo bioavailability
data [5,50]. Likewise, numerous studies confirmed the capability of IVPT methodology, if
properly conducted, to provide the same conclusions as in vivo clinical endpoint studies
regarding the bioequivalence of two semisolid drug products [5] (for details, please see
Raney et al. [5]). The human skin retains its barrier properties for percutaneous absorption
of different drugs following the excision from the body, and therefore, is recommended as
a membrane to establish product equivalence with respect to efficacy [15]. However, it is
important to emphasize that although this methodology has been used for almost half of a
century in in vitro drug penetration/permeation studies, it was not accepted by EMA for
the evaluation of topical semisolid products until 2018, due to difficulties in the procedure
validation. Namely, due to high variability of human skin (related to gender, race, age
and anatomical site), the method standardization and verification of reproducibility is a
quite challenging task [51]. Therefore, to manage the variability, EMA provides certain,
generalized recommendations for: (i) membrane choice (inclusion/exclusion skin sections,
skin preparation techniques, skin integrity, number of skin donors and replicates per
donor), (ii) choice of receptor medium (composition, criteria for acceptable sink conditions),
(iii) amount and method of formulation application, (iv) sampling time and test duration,
(v) analytical method used for drug quantification in receptor solution. Furthermore, it is
required to demonstrate the appropriate discriminatory power of IVPT using the batches
with significant alterations compared to the finished product (e.g., by changing the product
strength, quantitative composition, CQA and process parameters) [14]. Here, it should
be noted that a similar procedure for IVPT is also described in the FDA product-specific
guideline (Draft Guidance on Acyclovir), but again with more attention to detail regarding
the method development, validation, and statistical data analysis [44].
One of the main limitations of the proposed IVPT method is the relatively high
number of skin donors required to achieve optimal statistical power for the bioequivalence
demonstration. Due to the inherent variability in skin permeability, according to the EMA
draft guideline, 12 donors with at least two skin sections per donor are required [14].
The FDA does not define the exact number of donors (i.e., only requires multiple skin
donors), but a minimum of 4 replicate skin sections per donor per treatment group is
recommended [44]. However, it should be emphasized that, depending on the variability
of the obtained data, the number of skin donors should be further increased. In this context,
recently, Shin et al. [50] evaluated whether an IVPT method could be used to compare
the bioavailability of acyclovir from different commercially available creams. Due to the
large inter- and intra-donor variability of IVPT data, authors utilized a novel statistical
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approach adapting one previously developed to evaluate scaled average bioequivalence
(SABE) for highly variable drugs. The implementation of SABE analysis enabled them to
capitalize upon the ability of IVPT methodology to sensitively discriminate differences in
acyclovir permeation through the skin from any single individual, while compensating for
the variability from one individual compared to another [50]. In other words, this statistical
approach was shown to improve the power of comparative IVPT studies, thus reducing
the number of skin donors (16 donors with four replicates per donor per treatment group)
compared to traditional average bioequivalence analysis requiring almost 40 donors. As
authors concluded, the IVPT method, followed by an appropriate statistical analysis of the
obtained results, is a sensitive and discriminative test that can support the demonstration
of bioequivalence for topical semisolid drug products [50].
However, considering that the human skin is usually obtained from plastic surgeries,
it could be extremely difficult to procure a sufficient amount of ex vivo skin sections [5].
Therefore, in order to overcome the limitations in supplying excised human skin, animal
skin models (most frequently porcine ear skin) have been intensively used in the liter-
ature. Although several guidelines recommend the use of animal skin to predict local
bioavailability (e.g., SCCS/1358/10 for in vitro assessment of dermal absorption of cos-
metic ingredients [52], OECD for bioavailability evaluation of dermal products in 2010 [53])
or systemic absorption (EMA Guideline on quality of transdermal patches in 2014 [54]),
due to high variability in skin permeability of different animal models, it is quite difficult to
perform a valid comparison between the results obtained across various species [11,51,55].
Therefore, during the last two decades, the scientific community has shown increasing
interest in artificial skin surrogates for conducting in vitro permeation studies. Three
different types of skin surrogates have been intensively tested, including artificially cul-
tured human skin models (reconstructed human epidermis (e.g., EpiSkin™, EpiDerm™,
SkinEthic™, EpiCS®, Labcyte model) and the full human skin models (e.g., StrataTest®
model, GraftSkin®, Vitrolife-Skin™ model), parallel artificial membrane permeability as-
says (PAMPAs), and artificial membranes based on simple polymeric or lipid models (e.g.,
Strat-M™) [55]. Although these artificial skin surrogates offer numerous advantages (e.g.,
defined thickness, composition, ease in handling and storage, and reproducibility in the
permeation data), the correlation with the human data is often poor, due to inability to
completely recreate the heterogeneous nature of the skin, including cell metabolism and
skin appendages. Consequently, skin surrogates are currently recommended for the early
screening of different formulations, while human skin should be used for the in vitro
permeation testing of finished drug products [55,56].
3.2. Stratum Corneum (SC) Sampling
SC sampling (popularly called tape stripping) represents a simple, minimally invasive
(skin barrier properties are completely repaired within a few days) technique that involves
the sequential removal of superficial skin layers using adhesive tapes [5,9,14]. In case of
semisolid products that act on or in the SC, the measurement of drug concentrations in
the SC during uptake and elimination phases is directly relevant to characterizing the
rate and extent of drug at the site of action. Substantial evidence indicates that the rate
and extent of drug disposition in the SC also correlate with those attained into the viable
underlying tissues [5,14,57]. Therefore, for semisolid drug products acting beyond the SC,
tape stripping may provide a suitable surrogate to characterize the rate and extent of drug
absorption to deeper skin layers [5,14,57]. The SC sampling approach was first described
in a 1998 FDA Draft Guidance for Industry as a universal method for demonstrating
bioequivalence of all topical drug products [58]. This document was withdrawn four years
later, due to inconsistency in results found by two independent expert laboratories with
commercially available tretinoin gel products [5,9,57]. After 2002, considerable research
efforts have been focused on the refinement and improvement of the proposed methodology.
The tape stripping procedure recently described in the EMA draft guideline mainly relies
on the approach proposed by Professors Richard Guy and Annete Bunge in 2007–2009
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(e.g., [59,60]). Thus, in the following section, the most important features of this refined
methodology are presented in brief.
Instead of eight time points (four for uptake and four for elimination phase) required
to establish the kinetic profile of a drug within the SC according to original FDA draft
guidance [58], EMA proposed a simplified, two-time point method, whereby tape stripping
should be performed once in the uptake phase and once in the clearance phase [14]. During
the pilot study, the optimal uptake time should be established by testing multiple uptake
times to detect the time point from which the mass of drug recovered from the SC remains
constant (i.e., when diffusional steady state is achieved). The optimal clearance time
should be defined by detecting the time point at which at least 25% decrease in the mass
of drug recovered from the SC occurs, compared to the one achieved in the uptake phase
(should not exceed 48 h to avoid skin desquamation effects) [14]. However, it should
be emphasized that the selection of optimal time point has been the subject of various
criticism in the literature. For example, according to Rath and coworkers [61], the SC
sampling at the time point when the amount of drug in the SC has reached the steady
state can mask differences in formulations. For this reason, the approach described in
the FDA’s guidance for vasoconstrictor assay was proposed to ensure that the chosen
dose duration lies on the sensitive part of the dose-response curve [61]. Further, since
the contradictory results obtained between two laboratories following the FDA draft
guidance were inter alia attributed to differences in the control of lateral spreading from
the application site [60], to minimize inter-site variability, EMA recommends a double
template design for the sample application and SC sampling (one template delineating the
application area, another delineating the sampling area). Cleaning the skin surface has been
recognized as particularly important and has to be carefully validated, by demonstrating
the satisfactory recovery (>90%) of the drug formulation removed from the skin surface and
the negligible drug content (<10%) recovered by stripping the cleaned skin immediately
after application [14]. Unlike withdrawn FDA guidance that required the sequential
application and removal of 12 pieces of adhesive tapes [58], EMA defines that the minimum
and maximum number of tapes should be established based on transepidermal water loss
(TEWL) measurements (tape removal should be stopped when TEWL value exceeded eight
times the baseline pre-stripping value) [14]. Likewise, since the lack of assurance of “tape
equivalence” between different manufacturers but also within different batches/production
years of the same manufacturer, has been identified as one of the major weaknesses for
ensuring the appropriate reproducibility of the tape stripping protocol [9], EMA outlines
specific requirements that should be met for adhesive tapes. Instead of discarding the
first two tapes, as suggested by the withdrawn FDA draft guidance [58], all stripped
tapes from each treatment site should be analyzed, whereby the first two tapes should
be examined separately, and their contribution to the total amount of the drug recovered
should be evaluated [14]. Finally, the number of subjects involved in the study should
be justified based on the variability estimated from the pilot study and demonstrated to
be statistically relevant. A minimum of 12 subjects should be used for demonstration
of equivalence [14]. Since it was previously shown that duplicate application of each
formulation reduces the magnitude of variability in tape stripping data and improves its
reproducibility [59,62], according to EMA draft guideline, at least two application sites per
product (test, comparator and negative controls) per forearm (one for uptake and one for
elimination phase) should be involved [14]. Investigating the potential of tape stripping
in humans to assess bioequivalence of topical acyclovir cream products (the site of action
of acyclovir is beyond the SC, in the basal epidermis), Pensado et al. [57] observed high
within-subject standard deviation in the obtained mass per unit area of drug in the SC from
the selected reference product. Using SABE methodology proposed for assessing highly
variable IVPT data, it was estimated that 10–15 subjects are needed to achieve the statistical
power of at least 80%, while traditional average bioequivalence analysis is estimated to
require between 15 and 50 subjects [57]. Although widening of the bioequivalence limits
has been frequently proposed to reduce the number of subjects and to improve comparison
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efficiency, it lowers the standard for comparability of the test and reference products. In
contrast, SABE analysis with the traditional bioequivalence limit increases the power of the
study to an even greater degree than widening of the bioequivalence limits and, therefore,
could be more useful for demonstration of bioequivalence of highly variable drugs [57].
Since the protocol proposed in EMA draft guideline is quite cumbersome, Ozdin et al. [62]
suggested novel dermatopharmocokinetic approach based on only one dose duration during
the uptake phase to generate drug content in SC versus time profiles, whereby each time
point corresponds to one stripped layer. Population pharmacokinetics modeling, applying
ADAPT® 5 software (Biomedical Simulations Resource, Los Angeles, CA., USA) with
maximum likelihood expectation maximization (MLEM) algorithm, was used to fit the
obtained data and to estimate the rate and extent of drug absorption or input into the
skin. The rational for described concept comprising only one dose duration lies in the
fact that bioequivalence assessment is actually the test of formulation performance. The
performance of topical semisolid products comprises drug release from formulations and its
partitioning into the skin (following partitioning into the SC, drug penetration into deeper
skin layers depends on drug properties rather than on formulation performance). The
proposed approach based on population pharmacokinetic modeling was deemed successful
for topical semisolids, using the approved generic and reference acyclovir creams that were
shown to be bioequivalent in an appropriate clinical endpoint study. Although the estimates
of the rate and extent of drug absorption with population pharmacokinetic modeling were
associated with less inter-individual variability, despite the highly variable tape stripping
data, further studies are required to investigate feasibility and the discriminatory power of
this approach [62]. Finally, it is interesting to note that recently FDA approved a generic
diclofenac sodium topical gel (1%), based on the collective evidence including (i) Q1 and
Q2 sameness and physical and structural similarity to the reference product, (ii) an in vivo
bioequivalence study with pharmacokinetic endpoints, and (iii) a virtual bioequivalence
assessment leveraging dermal physiologically-based pharmacokinetic (PBPK) modeling
and simulation instead of a comparative clinical endpoint study in patients. The multi-
phase multi-layer (MPML) MechDermA model implemented within the Simcyp Simulator
(Certara, Princeton, NJ., USA) was used for PBPK modeling [63,64]. To the best of our
knowledge, this is the first ANDA approval utilizing the PBPK modeling to support the
bioequivalence of topical semisolid drug products.
4. Conclusions
The draft guideline on the quality and equivalence of topical products recently issued
by EMA represents a long-awaited regulatory advance regarding alternative approaches for
equivalence testing of topical products in lieu of therapeutic equivalence clinical trials. Gen-
erally, implementation of an extended pharmaceutical equivalence concept, supported by
appropriate in vitro and in vivo methodologies (depending on the complexity of product
being studied) will enable a reliable and scientifically driven assessment of bioequivalence
of topical generic products. The main identified constraints of the EMA draft guideline
which limit its successful translation into practice are mainly related to the quite restrictive
acceptance criteria regarding the extended pharmaceutical equivalence, product perfor-
mance, and efficacy documentation. In this context, it is expected that widening of the
acceptance range and/or adoption of proposed statistical approaches, taking into account
the intrinsic variability of product being studied will allow more efficient assertion of
the product equivalence, simultaneously maintaining the rigorous quality standards. All
proposed characterization methods, both in vitro and in vivo, have certain limitations, but
they do not have the same limitations, and information from one can complement another.
In other words, the collective weight of evidence obtained from comparing product quality
and performance is expected to facilitate the development, registration, and ultimately
approval of generic semisolid drug products. In this context, it is important to emphasize
that due to numerous challenges associated with the experimental analysis of CQA and
product transformation after administration, it would be helpful that EMA provides the
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closer recommendations for methods that should be used for their characterization. Finally,
it is reasonable to anticipate that, in the near future, a refined guideline will allow for a
significant increase in the availability of multisource generics on the market, which, in turn,
will improve patient access to more affordable topical dermatological drug products.
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